Ayala Pharmaceuticals Presents Positive Interim Data from Phase 2 ACCURACY Trial of AL101 for the treatment of Recurrent/Metastatic Adenoid Cystic Carcinoma with Notch Activating Mutations at ESMO 2020GlobeNewsWire • 09/18/20
Ayala Pharmaceuticals to Host Virtual KOL Event Reviewing Interim Data Presented at ESMO 2020 from Ongoing Phase 2 ACCURACY Trial of AL101 for the Treatment of Recurrent/Metastatic Adenoid Cystic CarcinomaGlobeNewsWire • 09/14/20
Ayala Pharmaceuticals Announces the Appointment of Vered Bisker-Leib, Ph.D. To Its Board of DirectorsGlobeNewsWire • 08/20/20
Ayala Pharmaceuticals Reports Second Quarter 2020 Financial Results and Provides Business UpdateGlobeNewsWire • 08/13/20
Ayala Pharmaceuticals to Present Updated Data from Ongoing Phase 2 ACCURACY Trial of AL101 for the Treatment of R/M Adenoid Cystic Carcinoma at the European Society for Medical Oncology (ESMO) Virtual Congress 2020GlobeNewsWire • 07/27/20
Ayala Pharmaceuticals Reports First Quarter 2020 Financial Results and Provides Business UpdateGlobeNewsWire • 06/22/20